Clinical trials: Dopamine
Parkinson Disease, Parkinson's Disease
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
Ropinirole Hydrochloride (ROP) was granted approval for the treatment of Parkinson's Disease (PD) on 20 October 2006. ROP is expected to be used for a long term in clinical practice.
- Trial name
- NCT00485069
- Testing
- ROP, ROP+L-Dopa
- Where
- 22 sites in Japan
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT00605683)
- Testing
- Safinamide (as add-on therapy)
- Where
- 125 sites in United States, Argentina and 18 more
- Volunteers
- 679 people
- Sponsor
- Newron Pharmaceuticals SPA
Idiopathic Parkinson's Disease
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the…
- Trial name
- SETTLE (NCT00627640)
- Testing
- Safinimide 50-100 mg/day
- Where
- 121 sites in United States, Australia and 19 more
- Volunteers
- 549 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
- Trial name
- NCT00522379
- Testing
- Rotigotine
- Where
- 77 sites in United States, Chile and 3 more
- Volunteers
- 514 people
- Sponsor
- UCB Pharma
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH302 (NCT00633880)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 181 people
- Sponsor
- Chelsea Therapeutics
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the…
- Trial name
- PARADIGM (NCT06360419)
- Testing
- Solriamfetol 300 mg
- Where
- 40 sites in United States
- Volunteers
- 346 people
- Sponsor
- Axsome Therapeutics, Inc.
ADHD
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.
- Trial name
- NCT07717892
- Testing
- Solriamfetol Dose A, Solriamfetol Dose B
- Where
- 28 sites in United States
- Volunteers
- 468 people
- Sponsor
- Axsome Therapeutics, Inc.
Restless Legs Syndrome
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in…
- Trial name
- NCT00367822
- Testing
- Lisuride, Ropinirole
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Axxonis Pharma AG
Healthy Subjects
Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.
The purpose of this study is to look at how much of a new drug, GSK598809 binds to specific proteins in the brain and how much stays in the blood over a range of different doses.
- Trial name
- NCT00468806
- Testing
- GSK598809, using [11C]-(+)-PHNO
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
- Trial name
- NCT07173738
- Testing
- BIA 5-1058, Furosemide, BIA 5-1058 and Furosemide
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
PARKINSON DISEASE (Disorder)
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
- Trial name
- Vista PD (NCT07804615)
- Testing
- VIM0423
- Where
- 30 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Vima Therapeutics
Parkinson Disease
A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging
This is a study of safinamide, an investigational drug for Parkinson disease (PD). Safinamide is being developed as add-on therapy for the treatment of Parkinson disease.
- Trial name
- NCT01264861
- Testing
- Safinamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Newron Pharmaceuticals SPA
Advanced Parkinson Disease
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating…
- Trial name
- SWITCH-ON (NCT07313176)
- Testing
- No Intervention
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 1 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Stroke Sequelae
Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke
Following stroke, a recovery process is promptly initiated, which leads to a partial rehabilitation. However, a number of disabling residual symptoms may persist for years and include mental fatigue, depression, cognitive…
- Trial name
- OSU6162DB003 (NCT04127669)
- Testing
- OSU 6162
- Where
- Sweden
- Volunteers
- 101 people
- Sponsor
- Arvid Carlsson Research AB
Narcolepsy, Obstructive Sleep Apnea
SUNOSI® (Solriamfetol) Pregnancy Registry
The SUNOSI (solriamfetol) Pregnancy Registry is a US- and Canada-based prospective, observational study to evaluate the safety of solriamfetol exposure during pregnancy in women with a diagnosis of narcolepsy or obstructive sleep…
- Conditions
- Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring
- Trial name
- NCT06413420
- Testing
- Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment
- Where
- 2 sites in United States
- Volunteers
- 1,731 people
- Sponsor
- Axsome Therapeutics, Inc.
Parkinson's Disease, Dyskinesia
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
- Trial name
- NCT00105521
- Testing
- Sarizotan
- Where
- 32 sites in United States
- Volunteers
- 398 people
- Sponsor
- EMD Serono